Nurexone to open exosome production facility in Indiana

Executive Summary

• Nurexone Biologic Inc.'s U.S. subsidiary, Exo-Top Inc., plans to establish its first U.S. commercial exosome production facility in Indianapolis, Indiana.
• The facility will serve as the U.S. manufacturing base, transferring Nurexone's proprietary exosome production process to the American market for both therapeutic pipeline use and B2B regenerative aesthetics.
• The move supports Nurexone's broader North American strategy, complementing progress toward first-in-human clinical trials for ExoPTEN and plans to uplist to a major U.S. stock exchange.

Key Details

• Facility Location: Indianapolis, Indiana.
• Purpose: To serve as Exo-Top's U.S. manufacturing base and anchor Nurexone's North American presence.
• Production Scope: The good-manufacturing-practice-compliant site will produce exosomes for:
  • Nurexone's therapeutic pipeline.
  • A growing business-to-business opportunity in regenerative aesthetics.
• Strategic Context: The expansion is supported by Indiana's life sciences cluster, logistics infrastructure, and incentives.
• Related Corporate Milestones: The facility establishment complements the company's progress toward first-in-human clinical trials of ExoPTEN and plans to uplist to a major U.S. stock exchange.

Notable Quotes

• Jacob Licht, CEO of Exo-Top: "Indiana's commitment to building its life sciences cluster, outstanding logistics and strong incentives offer make Indianapolis the ideal home for Exo-Top, and we are honoured to consider expanding into Indiana with the support of the Indiana Office of Commerce. By joining this ecosystem, we would contribute to Indiana's biomanufacturing growth while securing a U.S. foundation for our therapeutic and commercial programs."
• David Adams, Secretary of Commerce (Indiana): "Indiana would be a natural fit for Exo-Top's U.S. establishment, and we look forward to the potential high-quality jobs and local economic benefits this investment would create. The state offers the right environment for Exo-Top to scale production and strengthen Nurexone's U.S. supply chain."